Elicio Therapeutics, INC Schedule 13D activist filings
Filed when an investor crosses five percent and intends to influence the company — the activist disclosure.
NASDAQ
SCHEDULE 13D/A: Major Shareholder GKCC Increases Stake in Elicio Therapeutics, Provides $10 Million Senior Secured Note
GKCC, LLC and its manager Yekaterina Chudnovsky have increased their beneficial ownership in Elicio Therapeutics, Inc. to 48% through the issuance of new warrants and a $10 million senior secured promissory note.
NASDAQ
SCHEDULE 13D/A: Major Shareholder Converts $20 Million Note, Boosting Stake to 48.1% in Elicio Therapeutics
Elicio Therapeutics, Inc. announced that GKCC, LLC, an entity controlled by board member Yekaterina Chudnovsky, converted a $20.3 million convertible note into 3,500,573 shares, increasing their beneficial ownership to 48.1% of the company's common stock.